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Abstract  
New devices designed for minimally invasive closure of the left atrial appendage (LAA) may 
be a  viable  alternative  for  patients  in  whom anticoagulation  is  considered  high risk.  The 
Lariat (Sentreheart, Redwood City, CA), which is currently FDA-approved for percutaneous 
closure  of  tissue,  requires  both  trans-septal  puncture  and  epicardial  access.  However  it 
requires  no anticoagulation  after  the procedure.  Here we describe a  case of effusion and 
tamponade during a Lariat procedure with successful completion of the case and resolution of 
the  effusion.                                            
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Introduction
New devices designed for minimally invasive closure of the left atrial appendage (LAA) may 
be a  viable  alternative  for  patients  in  whom anticoagulation  is  considered  high risk.  The 
Lariat (Sentreheart, Redwood City, CA), which is currently FDA-approved for percutaneous 
closure  of  tissue,  requires  both  trans-septal  puncture  and  epicardial  access.  However  it 
requires  no anticoagulation  after  the procedure.  Here we describe a  case of effusion and 
tamponade during a Lariat procedure with successful completion of the case and resolution of 
the  effusion.                                                 
Case
An 87 year old man with longstanding persistent atrial fibrillation and elevated stroke risk 
(CHADSVASC score = 3,  HASBLED = 2)  was felt  not to  be candidate  for  chronic oral  
anticoagulation due to repeated falls associated with orthopedic injury.   He was referred to 
our Electrophysiology Laboratory for percutaneous suture ligation of the left atrial appendage. 
A pre-operative CT angiogram was performed to determine the patient's left atrial appendage 
anatomy.  This showed a single lobed appendage 3.3cm in length with a trabeculated distal 
portion and was deemed suitable for the exclusion procedure. Under general anesthesia, intra-
operative 3D transesophageal echocardiography (TEE) demonstrated no left atrial thrombus.   
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A Tuohy needle was used to enter  the pericardial  space via  a subxiphoid approach under 
fluoroscopic guidance.  Entry into the pericardial space was anterior-lateral, using contrast and 
a lateral fluoroscopic view.  The access site was sequentially dilated and a 13Fr sheath was 
placed into the pericardial space.  Next, trans-septal puncture was performed using an 8.5 Fr 
SL-1 sheath and an Extra Sharp Brokenbrough needle, via the right femoral vein. A Heparin 
drip  was  initiated  to  maintain  adequate  activated  clotting  time  (250-300  sec).
A left atrial angiogram with an occlusive balloon (SentreHeart Endocath) confirmed the LAA 
size,  shape  and  orientation,  consistent  with  CTA  findings.  A  magnet-tipped  guidewire 
(Sentreheart FindrWIRZ) wire was advanced into the distal portion of left atrial appendage.   
A second  magnet-tipped  guidewire  was  advanced  into  the  subxiphoid  space  and coupled 
magnetically to the LAA wire, in the end-to-end configuration.  The Lariat suture loop was 
then advanced into the pericardial space over the magnet guidewire.  The suture loop could 
not be advanced to the base of the appendage due to separation of the guidewire magnets. 
After manipulation of the suture loop the magnets were often noted to be in the end-to-side 
configuration,  preventing  successful  positioning  of  the  suture  loop.  
During manipulation of the magnet-tipped guidewires, the patient became hypotensive to a 
systolic pressure of 55 mmHg and a new pericardial effusion was noticed on TEE (Figure 1).  
Approximately 200cc of blood was drained from the side arm of the epicardial sheath with 
some  initial  improvement  in  hemodynamics.  The  effusion  reaccumulated  and  the  blood 
pressure dropped. A pigtail catheter was emergently placed in the pericardial space.  A total of 
800cc  was  drained  and  autotransfused  back  to  the  patient.  The  patient's  hemodynamic 
condition stabilized and the decision was made to continue the case.  Hemostasis of the LAA 
would  likely  be  achieved  with  successful  application  of  the  closure  device.  
Figure 1: A. Reconstructed CT scan demonstrating anatomic relationship of the LAA and the ideal trajectory of  
the sub-xiphoid epicardial  puncture.  B. Contrast injection into the LAA os after  closure of the Lariat  suture  
showing no flow into the appendage.  C. Intra-operative TEE prior to LAA closure demonstrates  pericardial 
effusion.
With  the  pigtail  catheter  in  place,  a  second  subxiphoid  epicardial  access  was  obtained, 
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directed more laterally from the first.  The epicardial needle was directed towards the magnet 
tipped wire already in the LAA.  The new orientation of the epicardial  sheath was felt  to 
improve  access  to  the  left  atrial  appendage.                                    
The Lariat was advanced into the subxiphoid space through a second 13Fr sheath and easily 
tracked over the guidewire around the base of left atrial appendage.   Appropriate position of 
the suture was confirmed with balloon inflation, atrial angiography, and color Doppler and 3D 
TEE  (Figure  2).                                        
Figure 2: A. Pre-operative appearance of the LAA on 2D TEE. B. Post-operative TEE shows no color flow into  
the LAA. Bottom panels show 3D TEE images of the LAA pre-  and post-operative (C and D, respectively)
The suture loop was successfully  deployed and there was no further  accumulation  of  the 
effusion.  Intra-op TEE showed no residual flow in the appendage.  The pigtail catheter was 
left  in place.  Protamine was administered to partially reverse anticoagulation.             
Follow-up transthoracic echocardiography 12 hours later showed no pericardial effusion and 
the pigtail catheter was removed.  The patient was later discharged home.                  
Discussion
Percutaneous  catheter-based  occlusion  of  the  LAA  is  a  viable  option  in  patients  with 
limitations to oral anticoagulation therapy [1,2].  Devices available to accomplish this include 
the WATCHMAN (Aritech, Inc, Plymouth, MN), the Amplatzer device (Amplatzer Products, 
Plymouth, MN) and the Lariat (SentreHEART, Inc, Palo Alto CA).                           
The WATCHMAN device is a self expanding nitinol frame that is delivered percutaneously 
through a trans-septal approach.   It is the only device currently undergoing FDA approval for 
stroke  prevention  in  atrial  fibrillation.   However  the  Watchman  LAA  occlusion  device 
requires 45 days of anticoagulation after implant. The Amplatzer device is now also being 
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evaluated for LAA occlusion.  Similar to the WATCHMAN device, initial anticoagulation is 
required  for  endothelialization  [3].                                         
The Lariat device is the only catheter-based non-intracardiac LAA closure device currently 
available.  It is 510(k) USFDA approved for the soft-tissue approximation and/or ligation with 
a pre- tied polyester suture.   Success is determined by angiography of the LAA and TEE 
color-flow Doppler.  In contrast to occlusion devices that leave a device in contact with the 
bloodstream, anticoagulation is not needed after the procedure. Patients who cannot tolerate a 
minimum of 45 days of anticoagulation therapy are not candidates for current intracardiac 
LAA  closure  devices  and  are  potential  candidates  for  a  Lariat  suture  closure  device.
Initial experience with the Lariat procedure is now being reported.  Early series in 3 centers 
show rate of acute or late effusion requiring intervention of 3.5 % (3 in 89 patients), 4% (1 in  
25 patients) and 15% (3 in 20 patients) [4-6]. For comparison, the atrial fibrillation ablation 
tamponade rate is 1.2% in experienced hands and the epicardial VT significant effusion rate is 
8% [7,8].   There has been one previously reported case of an LAA perforation during Lariat 
procedure with continuation of the procedure in order to not only ligate the LAA but also 
manage the complication.  In that  case there was no tamponade requiring drainage of the 
effusion, rather extravasation of contrast from the LAA angiogram was noticed on contrast 
injection  [9].                                               
An important  component  to  the  success  of  our  procedure  was  our  second  more  laterally 
oriented  access  to  the  epicardial  space,  directing  it  toward  the  appendage.  This  case 
emphasizes the importance of orientation of epicardial access.  In a series of 85 patients who 
had  successful  LAA  ligation,  17  of  85  required  a  second  pericardial  access  attempt 
predominantly because the initial pericardial access attempt was too posterior or too medial 
[4].  The  presence  of  the  endocardial  magnet-tipped  wire  already  in  the  LAA  offered 
directional  guidance.  Consideration  should  be  given  to  the  routine  placement  of  the 
endocardial wire in the LAA before epicardial access in LARIAT atrial appendage exclusion 
procedures.  
In  our  case,  intra-operative  development  of  tamponade  lead  us  to  consider  reversing 
anticoagulation and aborting the procedure.  However the onset of tamponade was delayed, 
well after the epicardial access, and did not occur until after extensive manipulation of the 
magnet-tip  guidewires.  This  scenario  favored  the  LAA  as  the  most  likely  source.   We 
recognized that  closing the LAA would result  in  cessation  of  bleeding and we elected  to 
continue  the  case  as  described.                                          
This  case  highlights  the  importance  of  the  lateral  placement  of  the  epicardial  sheath  and 
benefit obtained by having the endocardial wire in the LAA for guidance. It also illustrates 
how continuing with the Lariat snare suture exclusion of the LAA can treat the complication 
of  LAA  perforation.                                               
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